Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
P 2 (1)
P 4 (3)

Trial Status

Recruiting4
Not Yet Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT06650501Phase 4Recruiting

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

NCT06650488Phase 4Recruiting

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

NCT06637332Phase 4RecruitingPrimary

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

NCT04886284Phase 2Recruiting

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

NCT05361135Not ApplicableNot Yet Recruiting

18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia

Showing all 5 trials

Research Network

Activity Timeline